Jeff Jonas, Kenai Therapeutics chairman

'Sweet spot' of CNS cell ther­a­py: Ke­nai emerges with $82M for Parkin­son's study

One of the first drugs that Jeff Jonas filed for ap­proval was a Parkin­son’s dis­ease treat­ment. Now, a lit­tle over a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.